https://www.sciencedirect.com/science/article/abs/pii/S0531556517306757
https://journals.sagepub.com/doi/full/10.1177/26330040221150269
Galactose is super-glycating and addition of galactose to IgG seems the main factor in determining Glycanage
2 Likes
1. Table: IgG vs Ganglioside Sialylation Enzymes
System Main sialyltransferase(s) Linkage added Substrate backbone Where expressed IgG (Fc N-glycan) ST6GAL1 Adds α2,6 Neu5Ac to terminal galactose on N-glycans N-linked glycan (GlcNAc–Gal) on Fc Asn297 Broadly expressed in B-cells, hepatocytes, Golgi (minor: ST3GAL4/6) Adds α2,3 Neu5Ac (rare on IgG, more on other glycoproteins) N-linked glycans Hematopoietic & epithelial Gangliosides ST3GAL5 (GM3 synthase) Adds α2,3 Neu5Ac to galactose in LacCer → GM3 Glycosphingolipid (LacCer) Brain, immune cells ST8SIA1 Adds second Neu5Ac to GM3 → GD3 (disialylated) Glycosphingolipid Brain, thymus ST8SIA5 Extends further → GT1b, GQ1b (polysialylated) Glycosphingolipid Brain, especially during development
So:
- IgG = mainly ST6GAL1 (α2,6).
- Gangliosides = ST3GAL5 / ST8SIA family (α2,3 and polysialylation).
- Same donor, different enzymes, different linkages.
2. Shared Donor Substrate Pool: CMP-Neu5Ac
All sialyltransferases — whether they act on N-glycans (IgG) or glycolipids (gangliosides) — draw from the same cytosolic pool of activated sialic acid:
Pathway
- UDP-GlcNAc → ManNAc-6-P → Neu5Ac (sialic acid)
- Enzyme: GNE (UDP-GlcNAc 2-epimerase/N-acetylmannosamine kinase).
- Neu5Ac → CMP-Neu5Ac
- Enzyme: CMAS (CMP-sialic acid synthetase).
- CMP-Neu5Ac transported into the Golgi lumen by SLC35A1 (CMP-sialic acid transporter).
- Golgi-resident sialyltransferases (ST6GAL1, ST3GAL5, ST8SIA1/5) all use CMP-Neu5Ac as the activated sugar donor.
Why this matters
- The cytosolic supply of CMP-Neu5Ac is shared currency.
- If aging, inflammation, or metabolic shifts reduce Neu5Ac or CMP-Neu5Ac availability, both IgG glycans and gangliosides will show hypo-sialylation, even though they’re modified by different enzymes.
- Diseases that affect this pathway (e.g., SLC35A1 mutations → congenital disorders of glycosylation) show global hyposialylation across glycoproteins and glycolipids.
3. Aging Context
- With aging:
- CMP-Neu5Ac synthesis declines (less GNE activity, lower precursor availability).
- Golgi trafficking becomes less efficient.
- Inflammatory cytokines (TNF-α, IL-6) suppress ST6GAL1 and shift toward pro-inflammatory glycoforms.
- Net result:
- IgG: less α2,6-sialylation → pro-inflammatory Fc glycoforms (basis of GlycanAge biomarker).
- Gangliosides: less complex α2,8-polysialylation (loss of GT1b, GQ1b) → reduced synaptic stability, more GM1/GM3 dominance.
In short:
IgG glycans and gangliosides don’t share the same enzymes, but they compete for the same activated donor substrate (CMP-Neu5Ac). Aging reduces this pool and alters enzyme regulation, so both systems independently converge on the phenotype of loss of complex sialylation.
- N-acetylmannosamine (ManNAc)
- The committed precursor in the GNE step.
- Supplementing bypasses the rate-limiting GNE epimerase defect.
- Being clinically trialed for GNE myopathy (a rare disorder of sialic acid deficiency).
- Much more effective than free Neu5Ac at raising CMP-Neu5Ac pools.
You’re not wrong. GlycanAge is a decent barometer; it’s not the weather station. It mostly reflects how B cells are decorating IgG under the current cytokine/hormone/metabolic mood, not “inflammation in general.”
Here’s the clean split:
What GlycanAge actually tracks
- Chronic, systemic tone that pushes IgG toward less galactose/sialic acid when IL-6/TNF and metabolic noise are up. Also moves with menopause, adiposity, sleep, exercise, and weight loss.
- Adaptive humoral bias, not whether you “get sick a lot.” Exposure frequency isn’t the dial; the germinal-center milieu and plasma-cell glycosyltransferases are.
What it doesn’t capture well
- Tissue-local inflammation (gut, liver, brain microglia) that never bleeds into serum signals.
- Innate/trained immunity, complement, neutrophil priming, mast cells, NK cytotoxic tone, T-cell exhaustion, mucosal IgA, etc. Whole universes outside IgG.
- Acute spikes. It’s sluggish compared to hs-CRP or a cytokine panel.
Edge cases you’re hinting at
- A person with low infections can still have a “pro-inflammatory” IgG glycome if their baseline cytokine/metabolic state is off. Conversely, robust health plus low inflammatory tone can make IgG look “younger” even if they wrestle with germs like a champ. IgG glycan complexity isn’t a needs-based subscription plan.
How to read it like an adult
- Treat GlycanAge as one dial for chronic inflammatory/metabolic set point.
- Triangulate with a small, boring bundle: hs-CRP, GlycA (NMR), IL-6 or TNF-α if you must, CBC-diff for NLR, ferritin and fibrinogen, maybe ALT/AST and albumin. If you love data, add resting HRV for autonomic load.
- Watch directionality over time with stable routines. If the number trends better alongside CRP/GlycA, cool. If it wanders on its own, don’t let one glycan score gaslight you.
Bottom line: GlycanAge is a respectable proxy for the systemic humoral inflammatory set point, not a verdict on your entire immune ecosystem. Use it as a compass, not a courtroom.
also see posts on NEU1
4) Glycans / sialic acid rising: immune + tissue remodeling signatures
N-acetylneuraminate (sialic acid)
This is a big one in aging datasets. Sialic acids sit at the ends of glycans on proteins and lipids, and blood levels often track inflammation, tissue turnover, and disease burden. PMC+1
So “up only in EL” can mean:
- EL people may have distinct glycosylation/immune regulation (different “inflammaging” phenotype).
- Or you’re seeing a late-life remodeling signal that becomes prominent only at extreme ages (and the non-EL comparison group simply doesn’t reach that region in big enough numbers).
from alphagenome
This is not a “whole glycan machinery is broken” panel. It looks more like a biased remodeling pattern.
The cleanest system-level read is:
- more supportive on the CMP-sialic-acid supply / transport / alpha-2,6 sialylation side
- less supportive on the alpha-2,3 sialylation / some branching / some galactosylation side
- desialylation is split, not one-directional
- and the RNA story is much milder than the histone story, so this is a lean, not a catastrophic output collapse
Most believable supportive side
These are the ones I’d trust most because they are not just big on histones, but also look better on RNA:
- CMAS
- ST6GAL1
- SLC35A1
- SLC35A2
That combo is actually pretty coherent:
- CMAS helps activate sialic acid
- SLC35A1 transports CMP-sialic acid into the Golgi
- ST6GAL1 does alpha-2,6 sialylation
- SLC35A2 supports UDP-galactose transport, which helps terminal glycan elaboration more broadly
So that side does not look collapsed. In fact, it looks mildly supportive.
Strong histone-positive but less clean on RNA
These are real, but I would not worship them:
- B4GALT3
- NEU1
- NANS
They look strong at the dominant histone layer, but the RNA side is more mixed. So these are “interesting and probably real,” not “clean transcriptional wins.”
Most believable down-leaning side
These are the ones I’d take more seriously as actual weak-ish candidates:
- ST3GAL6
- ST3GAL4
- B4GALT1
- GNE
That pattern suggests weaker support for:
- alpha-2,3 sialylation (
ST3GAL4,ST3GAL6)- one important galactosyltransferase arm (
B4GALT1)- and one key upstream sialic acid biosynthesis step (
GNE)So you get this slightly weird but biologically plausible situation where:
- one part of sialylation supply looks up
- while another upstream or transferase branch looks down
That is not unusual. Cells love building pathways out of partial arguments.
Branching side
- MGAT3
- MGAT5
Both lean negative at the dominant layer. So if you were hoping for broad strong complex branching support, this panel is not giving that cleanly.
Desialylation side
This is split:
- NEU1 positive
- NEU3 negative
So it is not “desialylation globally high” or “globally low.”
It looks more like:
- lysosomal / recycling-side neuraminidase tone may be more supported
- membrane/ganglioside-side NEU3 tone may be less supported
That is actually a pretty meaningful distinction.
The oddball
- GALNT2 is the only real mixed locus
So O-glycosylation initiation does not resolve cleanly here.
If I compress it brutally
Best-supported glycan side
- CMAS
- ST6GAL1
- SLC35A1
- SLC35A2
Most likely down-leaning
- ST3GAL6
- ST3GAL4
- B4GALT1
- GNE
- with MGAT3/MGAT5 also leaning weaker on branching
Strong but not clean enough to overclaim
- B4GALT3
- NEU1
- NANS
Split / mixed
- GALNT2
- NEU1 vs NEU3 as a system
The best plain-English takeaway
Your glycanage panel does not read like a global glycosylation failure. It reads more like:
a shift toward stronger alpha-2,6 sialylation supply/transport, with weaker alpha-2,3 transferase and some branching/galactosylation components.
That is a pattern, not a collapse.
And because the RNA magnitudes are much smaller than the histone magnitudes, I’d treat this as:
mild transcriptional leaning plus bigger chromatin-state remodeling
not:
huge hard expression changes everywhere
Yes, partly. Your panel does show a version of that pattern, but not in a clean cartoon way.
What your data look like is:
- sialylation supply / transport / alpha-2,6 side looks relatively stronger
especially CMAS, ST6GAL1, SLC35A1, SLC35A2- some galactosylation / alpha-2,3 / branching side looks weaker
especially B4GALT1, ST3GAL4, ST3GAL6, MGAT3, MGAT5, GNESo the answer is yes, you do show signs of “some galactosylation weaker, some sialylation stronger.”
But the important catch is this:
for many glycans, sialic acid gets added onto galactose-containing termini.
So if galactosylation is weak, that can bottleneck how much of your stronger sialylation machinery can actually cash out into final glycan products. In other words:stronger sialylation machinery does not fully rescue weak galactosylation if the substrate architecture is missing.
Very annoying system design, but there it is.
That’s why your panel is better described as:
a skewed glycosylation profile
not
globally high sialylation
There’s another nuance that matters in your case:
- B4GALT1 is down-leaning
- but B4GALT3 is strongly positive at the dominant layer, even though its RNA side is mixed
So you do not look like “all galactosylation is weak.”
You look more like:one important galactosyltransferase branch is weaker, while another galactosylation-related branch may be partly compensating.
Same with sialylation:
- ST6GAL1 looks supportive
- but ST3GAL4/ST3GAL6 look down-leaning
So this is not “strong sialylation everywhere.” It’s more like:
alpha-2,6 side stronger
alpha-2,3 side weaker
That is a real pattern.
So the cleanest answer is:
Yes, your data show signs of weaker galactosylation in some branches together with stronger sialylation in some branches.
But biologically that would more likely produce a biased glycan remodeling pattern than a simple net increase in final sialylated glycans everywhere. Substrate bottlenecks still matter, because cells insist on making chemistry feel like office politics.